عـرض براءة الإختـراع

Multi-target drug candidates for the treatment of triple-negative breast cancer

• رقــم البراءة

  US 11,891,363 B1

• المجـال العلمى

  الصحة - Health

• سنة الإصدار

  2024

• مكتـب التسجيـل

  مكتب البراءات الأمريكي - US Patent Office

• أسماء المخترعين

  Shaaban; Saad (Al-Ahsa, SA), Ahmed; Hany Mohamed Abd El-Lateef (Al-Ahsa, SA), Alshemary; Bander (Al-Ahsa, SA)

• نبذة عن البـراءة

  Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.